Swipha is a Nigerian pharmaceutical company. It has received prequalification from the World Health Organization (WHO) for the production of sulfadoxine-pyrimethamine (SP), an effective medication for preventing malaria infection.
As a manufacturer of drugs, the National Agency for Food and drugs administration and control (NAFDAC) inspected the Swiss pharma plants according to its recent policy on establishing pharmaceutical plants in Nigeria.
NAFDAC is convinced that, with this policy implementation in SWIPHA, it is headed in the right direction to assure improved competitiveness of Nigerian Pharma Industry in the global space while projecting toward self-sufficiency in the production of essential medicines.
This feat was achieved after
the Pediatric Zinc Sulphate tablet (20mg dispersible tablet) manufactured by Swiss Pharma Nigeria Limited was added to WHO list of prequalified medicines on the second of May, 2023.
Hence, SWIPHA is the first manufacturer to be recognised by WHO as operating at an acceptable level of compliance to the GMP requirements in 2013. Thus, making Swiss pharma the first in West and Central
Africa.
The collaboration between NAFDAC and WHO is noteworthy. NAFDAC inspectors provided immense technical support before the site inspection of the WHO. Thus, identifying valuable insights into
objective review of Corrective and Preventive Actions (CAPA) taken to address the few observed non-conformances recorded during WHO’s inspection.
“This is aside several face-to-face meetings, phone calls and virtual meetings with key personnel of Swiss Pharma Nigeria, said the director General of NAFDAC.
Prof Mojisola Christianah Adeyeye, FAS
Director General/CEO 0pines that,
“This additional feat without an iota of doubt has reinforce our believe that with the right attitude, collaboration, synergy and appropriate policies, Nigeria Pharma Industries can become a force to reckon with in the comity of nations. With this achievement, Swiss Pharma Nigeria Limited has undoubtedly become the trail blazer, a global supplier of quality essential medicines for public health program and is set to improve its fair share of the Pharma market.
The top management of NAFDAC hereby encourage other well-meaning local drug manufacturers to emulate this feat through harmonization of collective aspiration and synergy of effort with the NAFDAC’s relevant directorates as we can together as a team achieve more.
She also emphasised that,
“As a customer-focused and Agency-minded organization, we are open to support more local manufacturers who have over the years shown a history of continued compliance to our extant regulations. Together, especially at a time like this in our Nation’s history when the Federal Government has pronounced executive orders to support indigenization of drug manufacturing, we can replicate this achievement and propel more local manufacturers to attain similar global recognition.
